NCT07063680View on ClinicalTrials.gov

Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Patients With Norepinephrine-refractory Vasoplegic Shock
Interventions
DRUG

Argipressin

Argipressin 0.4 U.ml-1 (i.e. 40IU diluted in 100ml 0.9% NaCl bag)

DRUG

Chlorure de sodium

NaCl 0.9%

OTHER

Collection of clinical data

At inclusion, D0 to D7, ICU discharge, D30 and D90

Trial Locations (1)

21000

CHU Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER